Research progress on the mechanism of new antidiabetic drugs in delaying cognitive impairment
10.3969/j.issn.1002-0152.2025.06.010
- VernacularTitle:新型降糖药延缓认知功能障碍的作用机制研究进展
- Author:
Yingjie FENG
1
;
Yajing WANG
;
Zifan ZHU
;
Na LUO
;
Penghua FANG
;
Zhenwen ZHANG
Author Information
1. 扬州大学附属苏北人民医院内分泌科 江苏省苏北人民医院(扬州 225001)
- Publication Type:Journal Article
- Keywords:
Diabetes;
Cognitive impairment;
Glucagon-like peptide-1 receptor agonists;
Sodium-glucose co-transporter 2 inhibitors;
Dipeptidyl peptidase 4 inhibitors
- From:
Chinese Journal of Nervous and Mental Diseases
2025;51(6):380-384,后插1
- CountryChina
- Language:Chinese
-
Abstract:
Patients with diabetes mellitus are at a significantly elevated risk of developing cognitive impairment,which adversely impacts their quality of life and imposes a substantial burden on the healthcare system.Novel antidiabetic agents,including sodium-glucose cotransporter 2 inhibitors(SGLT-2i),dipeptidyl peptidase-4 inhibitors(DPP-4i),glucagon-like peptide-1 receptor agonists(GLP-1RAs),and dual glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor agonists(e.g.,Tirzepatide),have been shown to not only effectively regulate glycemic control but also mitigate cognitive decline by inhibiting inflammation,reducing oxidative stress,preventing apoptosis,attenuating amyloid β-protein(Aβ)deposition,and suppressing tau protein phosphorylation.
